12:00 AM
 | 
Jun 18, 2012
 |  BC Week In Review  |  Company News  |  Deals

Proximagen, Upsher-Smith deal

Specialty pharma Upsher-Smith will acquire the 84% of Proximagen it does not already own for 320p per share in cash. The price, which values Proximagen at about £223 million ($345.7 million), is a 16% premium to Proximagen's close of 275p on June 12, before the deal was announced. Proximagen shareholders will also receive a contingent value right worth up to 192p per share,...

Read the full 294 word article

User Sign in

Trial Subscription

Get a 4-week free trial subscription to BioCentury Week In Review

Article Purchase

$30 USD
More Info >